Acumetis

Sales & Marketing

Kevin Asher leads Acumetis's Medical Practice, bringing 15+ years in Medical Affairs to teams across the industry.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.